Clinical Trials Logo

Schizophrenic Disorders clinical trials

View clinical trials related to Schizophrenic Disorders.

Filter by:

NCT ID: NCT00488319 Completed - Schizophrenia Clinical Trials

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.

NCT ID: NCT00485823 Completed - Clinical trials for Schizophrenic Disorders

Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

Start date: December 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to develop the weight management program, which is combined with healthy diet, proper physical exercise, and behavior modification, related to patient's quality of life. The patients groups are in routine practice with 5-20 mg olanzapine. The study results may be utilized for patients who have gained weight on olanzapine and also other antipsychotic drugs.

NCT ID: NCT00328276 Completed - Psychotic Disorders Clinical Trials

Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia

Start date: December 2004
Phase: Phase 2
Study type: Interventional

The etiology of schizophrenia remains unclear. Schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments. In addition to dopamine system hyperactivity, hypofunction of N-methyl-D-aspartate (NMDA) receptor plays a role in the pathophysiology of schizophrenia. Consequently, enhancing NMDA receptor neurotransmission has been considered as a novel treatment approach. To date, there have been several trials on NMDA enhancers reported. For example, sarcosine (N-methylglycine, a glycine transporter I inhibitor) showed therapeutic effects not only in chronically stable patients but also in acutely exacerbated ones when added-on to antipsychotics. In addition, sarcosine yields excellent safety profiles, in comparison to current antipsychotics. It remains unclear whether NMDA enhancers, such as sarcosine, can serve as monotherapy for schizophrenia. The aims of this project are to examine the efficacy and safety of sarcosine monotherapy for acutely-ill schizophrenic patients, and to compare the effects of 2 grams/day, effective dose, with 1 gram/day, ineffective lower dose.

NCT ID: NCT00088491 Completed - Clinical trials for Schizophrenic Disorders

Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

Start date: June 2004
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine depot; and determine the blood levels of IM olanzapine depot in patients at different points in time after an injection.

NCT ID: NCT00088465 Completed - Clinical trials for Schizoaffective Disorder

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Start date: August 2004
Phase: Phase 3
Study type: Interventional

This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: - Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, - Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, - Determine the blood levels of IM olanzapine depot in patients during long-term treatment